Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) Gross Margin (2016 - 2024)

Regenxbio has reported Gross Margin over the past 11 years, most recently at 70.22% for Q4 2024.

  • Quarterly results put Gross Margin at 70.22% for Q4 2024, up 2081.0% from a year ago — trailing twelve months through Dec 2024 was 59.72% (up 95.0% YoY), and the annual figure for FY2024 was 59.72%, up 95.0%.
  • Gross Margin for Q4 2024 was 70.22% at Regenxbio, up from 48.81% in the prior quarter.
  • Over the last five years, Gross Margin for RGNX hit a ceiling of 94.22% in Q4 2021 and a floor of 29.26% in Q1 2022.
  • Median Gross Margin over the past 5 years was 58.19% (2022), compared with a mean of 62.32%.
  • Biggest five-year swings in Gross Margin: tumbled -4505bps in 2022 and later soared 4925bps in 2023.
  • Regenxbio's Gross Margin stood at 52.17% in 2020, then surged by 81bps to 94.22% in 2021, then plummeted by -37bps to 59.22% in 2022, then decreased by -17bps to 49.41% in 2023, then soared by 42bps to 70.22% in 2024.
  • The last three reported values for Gross Margin were 70.22% (Q4 2024), 48.81% (Q3 2024), and 52.55% (Q2 2024) per Business Quant data.